Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 67

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 67
---
 amount of the purchase price of the acquired treasury shares as a negative position through the creation of a special reserve on its balance sheet. The Company may face negative Swiss tax implications, if it holds more than 10% of its own shares or retains treasury shares for a period exceeding six years. This 6 -yearperiod stands still, if the own shares were purchased due to obligations triggered by convertible bonds, option bonds or by employee participation plans, as long as such obligation duly exists (in case of an employee participation plan, however, for a maximum period of 6 years, i.e., in total 12 years). Common Shares In January 2025, the Company sold 161,290common shares for $ 3.10per share and received $ 500,000of gross proceeds. This issuance of common shares at $ 3.10triggered the Down Round Provision included in the outstanding Preferred Shares that were issued in October 2024. See detailed disclosures regarding the financial statement impact of this trigger below. On March 31, 2025, the Company entered into a Common Shares Purchase Agreement (the “ELOC SPA”) with Alpha Capital Anstalt (“Alpha”), relating to a committed equity line of credit. Pursuant to the ELOC SPA, the Company has the right from time to time at its option to sell to Alpha up to $ 25.0million of Company common shares, subject to certain conditions and limitations set forth in the ELOC SPA. The purchase price of the common shares that the Company elects to sell to Alpha pursuant to the ELOC SPA will be 95% of the volume weighted average price of the common shares during the applicable purchase date on which the Company has timely delivered written notice to Alpha directing it to purchase Company common shares under the ELOC SPA. In connection with the execution of the ELOC SPA, the Company issued a pre -fundedwarrant to purchase 192,308common shares at par value as consideration for its irrevocable commitment to purchase the common shares upon the terms and subject to the satisfaction of the conditions set forth in the ELOC SPA. As of June 30, 2025, no shares have been sold under the ELOC SPA. The Company has reflected the estimated fair value of the pre -fundedwarrants of $ 296,154issued to Alpha in connection with the ELOC SPA as a deferred offering cost and additional paid -incapital which is included in prepaid expenses and other current assets on the accompanying balance sheet as